Results 161 to 170 of about 78,982 (256)

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Advanced and More Symptomatic B-Cell Non-Hodgkin Lymphoma at Diagnosis After COVID-19 Disruptions in a Romanian Tertiary Center. [PDF]

Cureus
Toboltoc PC, Vekony A, Ioana G.
europepmc   +1 more source

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. [PDF]

Clinicoecon Outcomes Res
Li B, Yang J, Li J, Huang J, Li Z.
europepmc   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma. [PDF]

J Clin Med
Atacan H, Aslan V, Topal A, Mammadzada N, Yıldırım G, Güneysu GG, Karadurmuş B, Kaplan Tüzün E, Kuzu ÖF, Erdat EC, Aykan MB, Ertürk İ, Karadurmuş N.   +12 more
europepmc   +1 more source

Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma.
Karan Gowda, Medha Gupta, Adrian Aguilar, Carlos Cruz, Amanda Warner, Elizabeth R. Rodriguez, Sairah Ahmed, Branko Cuglievan, Joel Milam, David R. Freyer, Kimberly A. Miller, Greg Aune, Debra Eshelman‐Kent, Karen Albritton, Efstratios Koutroumpakis, Michael E. Roth, Jian Wang, Michelle A. T. Hildebrandt   +17 more
wiley   +1 more source

Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children. [PDF]

Clin Case Rep
Evele G, Francine K, Bardin R.
europepmc   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, EarlyView.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

A combined hematological and molecular study of Hodgkin lymphoma in Palestine: insights into subtype-specific prognosis and the role of Claudin-6/GATA-4. [PDF]

Ann Hematol
Asees M, Amer J, Rezeq A, Salhab A, Abdalhaq T.   +4 more
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source